RNA, U6atac small nuclear 39, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC39P profile across patient tissues and cancer cell-line models. RNU6ATAC39P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC39P is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, RNU6ATAC39P RNA expression shows 8,782 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, THCA, and THYM as cancer lineages where RNU6ATAC39P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC39P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC39P survival associations across molecular data types. RNU6ATAC39P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC39P RNA expression–survival associations across cancer types. High RNU6ATAC39P expression shows unfavorable associations in READ, KIRC, UCS and LAML, but favorable associations in MESO and HNSC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for RNU6ATAC39P RNA expression.
This table summarizes RNU6ATAC39P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC39P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC39P shows lower tumor expression in THCA, LUSC, UCEC and BLCA and higher tumor expression in ESCA and KIRC. The THCA box plot shows higher RNU6ATAC39P RNA expression in normal versus tumor tissue (log2 FC = −0.245, t-test p < 0.001).
This table shows molecular features associated with RNU6ATAC39P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC39P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
